Our Company

We are an innovative biopharmaceutical company developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases.

Our mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need.

A note
from our
CEO

Reenie McCarthy

At Stealth BioTherapeutics, our work is personal. We believe strongly in the potential of our science to deliver new treatment solutions and improve quality of life for patients with diseases involving mitochondrial dysfunction. Many of the diseases we are targeting currently have no FDA-approved treatments, presenting a significant unmet medical need that we hope to help address. Our team works closely with patients and healthcare professionals to achieve our mission of developing therapies for rare and common age-related diseases involving mitochondrial dysfunction. We collaborate closely with patient advocacy to understand how these diseases impact the daily lives of patients and to better inform our clinical development efforts. We also partner with leading institutions, physicians and scientists to develop our mitochondrial therapies. In preclinical studies, elamipretide has been shown to restore mitochondrial function at the cellular level with resulting improvement in the function of organ systems such as skeletal muscle, eye, brain, heart and kidney.14-19 Our hope is that this investigational therapy will help improve the prognosis and quality of life for patients and families whose lives are touched by mitochondrial disease.

Meet Our Leadership Team

We are invested in patient-focused therapeutic development and driven by a desire to help patients with unmet clinical needs. Our team brings a wealth of executive experience in their respective fields to Stealth BioTherapeutics.

Careers at Stealth

We are an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet clinical needs our programs seek to address.

We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates.

We continue to expand our broad knowledge of mitochondrial biology and novel chemistries to advance our mitochondrial programs and pipeline candidates. We are a high-energy, innovative company with a hard-working team striving to further our mission of patient-focused therapeutics development.

To learn more about joining our team, please click on the links below to see current open positions at Stealth.

Vice President, Pharmaceutical Sciences and Technical Operations

Contact: careers@stealthbt.com

Stealth BioTherapeutics is an Equal Opportunity Employer and an E-Verify Employer.

Note to Employment Agencies: Please do not forward agency résumés. Stealth BioTherapeutics is not responsible for any fees related to résumés that are unsolicited.

Contact Us

Stealth BioTherapeutics Inc.

123 Highland Ave, Suite 201, Needham, MA 02494

(617) 600-6888

info@stealthbt.com

Media Inquiries

media@stealthbt.com

Investor Inquiries

IR@stealthbt.com